Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents

A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis

David C. Henderson, MD; Enrico Cagliero, MD; Paul M. Copeland, MD; Christina P. Borba, BS, MPH; Eden Evins, MD; Doug Hayden, MA; Mary T. Weber, PhD, APRN, BC, PMHNP; Ellen J. Anderson, MS, RD, LDN; David B. Allison, PhD; Tara B. Daley, BS, MPH; David Schoenfeld, PhD; Donald C. Goff, MD

**Background:** While the incidence of new-onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes.

**Objective:** To study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test.

**Design:** A cross-sectional design in stable, treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis.

**Setting:** Subjects were recruited from an urban community mental health clinic and were studied at a general clinical research center.

**Patients:** Fifty subjects signed informed consent and 41 underwent the frequently sampled intravenous glucose tolerance test. Thirty-six nonobese subjects with schizophrenia or schizoaffective disorder, matched by body mass index and treated with either clozapine, olanzapine, or risperidone, were included in the analysis.

**Main Outcome Measures:** Fasting plasma glucose and fasting serum insulin levels, insulin sensitivity index, homeostasis model assessment of insulin resistance, and glucose effectiveness.

**Results:** The mean±SD duration of treatment with the identified atypical antipsychotic agent was 68.3±28.9 months (clozapine), 29.5±17.5 months (olanzapine), and 40.9±33.7 (risperidone). Fasting serum insulin concentrations differed among groups (F33=3.35; P=.047) (clozapine>olanzapine> risperidone) with significant differences between clozapine and risperidone (t33=2.32; P=.03) and olanzapine and risperidone (t33=2.15; P=.04). There was a significant difference in insulin sensitivity index among groups (F33=10.66; P<.001) (clozapine<olanzapine<risperidone), with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone (clozapine vs risperidone, t33=−4.29; P<.001; olanzapine vs risperidone, t33=−3.62; P=.001 [P<.001]). The homeostasis model assessment of insulin resistance also differed significantly among groups (F33=4.92; P=.01) (clozapine<olanzapine<risperidone) (clozapine vs risperidone, t33=2.94; P=.006; olanzapine vs risperidone, t33=2.42; P=.02). There was a significant difference among groups in glucose effectiveness (F33=4.18; P=.02) (clozapine<olanzapine<risperidone) with significant differences between clozapine and risperidone (t33=−2.59; P=.02) and olanzapine and risperidone (t33=−2.34; P=.03).

**Conclusions:** Both nonobese clozapine- and olanzapine-treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone-treated subjects. Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences.

Arch Gen Psychiatry. 2005;62:19-28

©2005 American Medical Association. All rights reserved.
In a nonrandomized, cross-sectional study, Melkersson et al found elevated fasting serum insulin levels and reduced growth hormone–dependent insulin-like growth factor 1 in 13 patients with schizophrenia treated with clozapine compared with 28 patients treated with conventional antipsychotic agents, which is suggestive of insulin resistance despite no significant difference between groups in body mass index (BMI). Olanzapine treatment similarly resulted in elevated serum levels of insulin, in addition to weight gain and elevations of serum leptin and lipid concentrations compared with baseline in a naturalistic 5-month follow-up study of 14 patients with schizophrenia. Newcomer et al reported elevated serum glucose levels at baseline and following a modified oral glucose tolerance test in patients with schizophrenia treated with clozapine and olanzapine compared with age- and weight-matched subjects treated with typical antipsychotic agents and untreated healthy controls. Elevations in fasting and postload serum glucose levels in patients treated with risperidone differed only in comparison with untreated healthy control subjects. Insulin resistance, calculated by the homeostasis model assessment of insulin resistance (HOMA-IR), was significantly greater in subjects treated with olanzapine and clozapine compared with patients treated with haloperidol and untreated normal controls, but this measure of insulin resistance did not differentiate the risperidone group from the haloperidol-treated group. Finally, in a naturalistic study of 82 patients with schizophrenia who switched from taking conventional antipsychotic agents to clozapine at a mean age of 27 years, 37% developed new-onset diabetes mellitus during a 5-year follow-up period. Weight significantly increased over time and correlated with an increase in total serum cholesterol and serum triglyceride levels. There also was a significant increase in serum triglyceride level.

Pharmacoepidemiological studies have yielded mixed results. Of 8 published studies examining large, independent databases, 5 found clozapine and/or olanzapine use associated with higher rates of diabetes mellitus compared with conventional antipsychotic agents or risperidone. Suggested atypical antipsychotic agents as a class were associated with greater risk compared with conventional antipsychotic agents. I found the conventional agents chlorpromazine and thioridazine associated with greater risk compared with clozapine; and I suggested that both conventional and atypical antipsychotic agents were associated with increased risk for diabetes compared with a general medical patient population. Although methodological issues related to nonrandom prescribing patterns and insensitive or nonuniform ascertainment of diabetes mellitus make these results difficult to interpret, clozapine and olanzapine have been most strongly implicated in pharmacoepidemiological studies.

Additionally, a group from the Food and Drug Administration research program compiled MedWatch reports of exacerbation of existing diabetes mellitus, new-onset diabetes mellitus, diabetic ketoacidosis, and hyperosmolar nonketotic diabetic coma in patients treated with clozapine and olanzapine. The clinical characteristics of the diabetic ketoacidosis cases were more consistent with type 2 rather than type 1 diabetes mellitus. The number of cases, temporal relation to initiation of treatment, and observation that diabetes mellitus resolved completely in several cases when the atypical antipsychotic agent was discontinued, only to return on rechallenge, suggested a plausible association between treatment with these 2 drugs and impaired glycemic control. However, the reports also highlighted cases where the diabetes mellitus did not resolve on discontinuation of the antipsychotic agent. Risperidone also has been linked more recently to reports of new-onset diabetes mellitus and diabetic ketoacidosis by the Food and Drug Administration research and MedWatch surveillance program, although the reports are fewer in number compared with clozapine and olanzapine despite a substantially greater exposure in terms of patient-years. While the incidence of new-onset diabetes mellitus appears to be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents, it remains unclear whether atypical antipsychotic agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes, such as obesity, lipid abnormalities, and decreased activity secondary to sedative effects. Identification of mechanisms contributing to a putative increased risk of diabetes with atypical agents may help explain apparent inconsistencies in results between pharmacoepidemiological studies and allow identification of patients at risk.

Finally, effects of atypical antipsychotic agents on glucose metabolism may be complicated by impairments of glucose metabolism possibly associated with schizophrenia and with the stress of acutely untreated psychosis. As a first approach to the examination of drug effects on glucose metabolism, we chose to study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test (FSIVGTT) and minimal model analysis. The FSIVGTT is a well-established, standardized method for assessing glucose metabolism and has been widely used in the medical fields of diabetes and obesity research in both small-scale and large population-based studies. A cross-sectional design in stable, treated patients with schizophrenia or schizoaffective disorder was chosen to allow comparison of nonobese patient groups matched by BMI. This design also minimizes the confounding effect of differential weight gain between antipsychotic agents, which would be expected in a prospective treatment study, and eliminates the stress effects of untreated illness on glucose metabolism.

**METHODS**

Subjects were recruited from an urban community mental health clinic and were studied at the Mallinckrodt General Clinical Research Center at Massachusetts General Hospital, Boston. The study was approved by the institutional review boards of Massachusetts General Hospital and the Massachusetts Department of Mental Health. Outpatients between the ages of 18 and 65 years with the diagnosis of schizophrenia or schizoaffective disorder and a BMI less than 30 kg/m² were eligible for the study. Patients were excluded on the basis of current substance abuse; diabetes mellitus; thyroid disease; pregnancy; significant medical illness...
including severe cardiovascular, hepatic, or renal disease; or unstable psychiatric illness. Eligibility was determined by interview and a medical record review for history and recent laboratory values. No screening laboratory tests were performed prior to the procedure. Patients treated with the following medications known to affect glucose tolerance were also excluded: birth control pills containing norgestrel, steroids, β blockers, anti-inflammatory drugs (including aspirin and ibuprofen), thiazide diuretics, agents that induce weight loss, and valproate sodium. A urine pregnancy test was performed prior to the study for female subjects of childbearing potential. Additionally, as the lutal phase is associated with a reduction in insulin sensitivity, menstruating women (n=6) were interviewed on their menstrual history and date of last menses, instructed to keep a log, and underwent the procedure during the early follicular phase of their menstrual cycle (days 1-7).

After providing written informed consent, subjects underwent a diagnostic evaluation by a research psychiatrist using the Structured Clinical Interview for DSM-IV. Subjects were given a diet plan calculated to maintain body weight and to provide a minimum of 250 g of carbohydrate for each of the 3 days prior to the FSIVGTT. Subjects were also instructed to fast for 12 hours preceding the FSIVGTT and to hold their morning medications the day of the test. Family, residential program staff, and outreach workers assisted subjects to maintain a high-carbohydrate intake and to guarantee fasting. Subjects were admitted to the Mallinckrodt General Clinical Research Center at 6:45 AM on the morning of the test. A complete nutritional assessment was conducted on admission and immediately prior to the initiation of the FSIVGTT.

**NUTRITIONAL ASSESSMENT**

Height was measured using a Harpenden stadiometer, which was calibrated on a weekly basis. Subjects were weighed on a digital electronic scale, and weight was recorded to the nearest 0.1 kg. The ideal body weight percentage was determined using Metropolitan Life Insurance tables using elbow breadth for frame size determination and actual measured height. Circumferences were measured at the narrowest waist, umbilicus waist, iliac waist, and broadest hip (buttocks). Waist-hip ratio was calculated as iliac waist measure relative to the widest hip circumference. Body fat percentage was calculated from skinfold measurements of the biceps, triceps, suprailiac, and subscapular.

A 4-day food record was obtained from each participant. Energy and nutrient intake were analyzed using an extensive nutrient database (Minnesota Nutrient Data System). Bioelectrical impedance was used to estimate body composition; the total conductive volume of the body is equivalent to total body water. Predictive equations were used to estimate total body water and body cell mass percentage as a function of impedance, height, weight, age, and sex. Indirect calorimetry measures were obtained with subjects in an alert, fasting state, resting state, and occupational activity components. The resting energy expenditure was calculated. A quantitative activity questionnaire (Modifiable Activity Questionnaire) was used to assess both leisure and occupational activity components.

**FREQUENTLY SAMPLED INTRAVENOUS GLUCOSE TOLERANCE TEST**

Two intravenous catheters were placed in antecubital veins (1 in each arm). Baseline blood samples were drawn for fasting plasma glucose and serum insulin levels, basic chemistry profiles, serum cortisol level, lipid profile, complete blood count, serum leptin level, and serum risperidone, clozapine, or olanzapine concentrations 10 minutes prior to the glucose infusion (time, 10 minutes). Subjects with possible diabetes mellitus (fasting plasma glucose level ≥126 mg/dl [6.99 mmol/l]) at baseline were dropped from study. Glucose 0.3 g/kg in normal saline was administered intravenously for 30 seconds at time 0. Approximately 2-ml blood samples were withdrawn at −10, −5, 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 21, 22, 23, 24, 25, 27, 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 90, 100, 110, 120, 140, 160, and 180 minutes for measurement of plasma glucose and serum insulin concentrations. Twenty minutes after the glucose infusion, 500 mg of tolbutamide (Upjohn Co, Kalamazoo, Mich) was administered intravenously for 45 seconds. Vital signs and plasma glucose concentrations were monitored throughout the procedure. Samples for glucose were collected in a gray-top tube containing sodium fluoride and potassium oxalate and analyzed immediately in the Massachusetts General Hospital Chemistry Laboratory. Samples for insulin were collected in a red-top tube (no additives). The samples were allowed to clot at room temperature, spun, separated, and immediately stored in cloudy falcon tubes at −80°C.

**LABORATORY ASSAYS**

Laboratory assays were performed by the chemistry laboratory and the Mallinckrodt General Clinical Research Center Core Laboratory of Massachusetts General Hospital. Insulin immunometric assays were performed using an Immulite Analyzer (Diagnostic Product Corp; Los Angeles, Calif) with an intra-assay coefficient of variation of 4.2% to 7.6%. Fasting plasma glucose level was measured with a hexokinase reagent kit (A-gent glucose test; Abbott, South Pasadena, Calif). Glucose assays were run in duplicate, and the intra-assay coefficient of variation ranged from 2% to 3%. Fasting total plasma cholesterol and triglyceride levels were measured enzymatically with an intra-assay coefficient of variation of 1.7% to 2.7% and 0.9% to 1.2%, respectively. The high-density lipoprotein cholesterol fraction was measured after precipitation of low-density and very low-density lipoproteins with dextran sulfate-magnesium with an intra-assay coefficient of variation of 0.89% to 1.82%. Low-density lipoprotein cholesterol values were estimated indirectly for participants with plasma triglyceride levels less than 400 mg/dl (4.52 mmol/l). Leptin level was measured by a radioimmunoassay with a coefficient of variation of 3.4% to 8.3% (Linco Human RIA kit [DSL-53100]; Linco Research, Inc, St Charles, Mo). Cortisol level was measured by competitive immunnoassay with an intra-assay coefficient of variation of 6.8% to 9.0% (Immulate Cortisol; Diagnostic Products Corp, Los Angeles, Calif). Growth hormone level was measured using immunoradiometric assay (Nichols Institute Diagnostics, San Clemente, Calif) with an intra-assay coefficient of variation of 1.6% to 8.1%.

**MINIMAL MODEL CALCULATIONS**

Insulin sensitivity index (SI), glucose effectiveness (SG), and the acute insulin response to glucose (AIRG) were calculated from plasma glucose and serum insulin values using the MINMOD version 3.0 computer program developed by Richard Bergman, PhD. The SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load. The SG represents the net fractional glucose clearance rate due to the increase in glucose independent of any increase in circulating insulin concentrations above baseline. The AIRG measures the acute (0-10 minutes) β-cell response to a glucose load calculated by the areas under the curve higher than basal insulin val-
ties. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 minutes of the FSIVGTT. The disposition index (which equals SI × AIRG), an index of β-cell function that takes account of prevailing insulin sensitivity and exploits the hyperbolic relationship between the 2, was calculated by the method described by Kahn et al. 40

HOMEOSTASIS MODEL OF ASSESSMENT OF INSULIN RESISTANCE

The HOMA-IR is an alternative method to assess insulin resistance and β-cell function on the basis of known relationships with fasting plasma glucose and serum insulin concentrations. The HOMA-IR was calculated by the following formula: fasting serum insulin concentration × fasting plasma glucose concentration/22.5. The HOMA-IR was calculated by taking the mean of 3 fasting values (times, −10, −5, and 0).

STATISTICAL METHODS

The primary outcome variables were fasting plasma glucose and serum insulin levels, HOMA-IR, SI, SG, and AIRG. Covariates included lipid concentrations, waist-hip ratios, and the Modifiable Activity Questionnaire. Descriptive statistics are represented as mean±SD. Within-group correlation coefficients were determined between indices of medication dose and blood levels, plasma glucose level, serum insulin level, HOMA-IR, SI, SG, and AIRG. Analysis of variance was used to compare the 3 antipsychotic agent groups for the following variables: fasting plasma glucose level, fasting serum insulin level, SI, HOMA-IR, SG, and AIRG. Analysis of variance was used to compare the 3 antipsychotic agent groups for the following variables: fasting plasma glucose level, fasting serum insulin level, SI, HOMA-IR, SG, growth hormone level, cortisol level, serum lipid level, leptin level, BMI, skinfold (triceps, biceps, suprailiac, subscapular, body fat percentage), bioimpedance analysis of body fat, waist-hip ratios, widest hip circumference, Modifiable Activity Questionnaire, resting energy expenditure, dietary assessment variables, serum insulin levels, HOMA-IR, SI, SG, and AIRG. Covariates differed among groups (F 33 =4.92; P <0.001) (clozapine >olanzapine >risperidone), with subjects treated with clozapine and olanzapine exhibiting significant insulin resistance compared with subjects treated with risperidone (clozapine vs risperidone, t 33 =−4.29; P <0.001; olanzapine vs risperidone, t 33 =−3.62; P =0.001) but not clozapine and olanzapine (t 33 =−0.67; P =0.51). While SI varies across studies and ethnic groups, we rely on data from the general population to understand the direction of insulin resistance. 34-36 The SI is inversely proportional to insulin resistance (lower SI indicates greater insulin resistance or less insulin sensitivity).

Insulin resistance calculated by the HOMA-IR also differed significantly among groups (F 33 =4.92; P =0.01) (clozapine >olanzapine >risperidone) treated with clozapine vs risperidone (t 33 =2.94; P =0.006) and olanzapine vs risperidone (t 33 =2.42; P =0.02) but not clozapine and olanzapine (t 33 =0.52; P =0.61). Both the clozapine and olanzapine groups displayed elevations in HOMA-IR compared with the risperidone group. The HOMA-IR and SI were significantly inversely correlated for patients treated with olanzapine (r =−0.72; P =0.01) and risperidone (r =−0.67; P =0.02) but not clozapine (r =−0.41; P =0.18).

GLUCOSE METABOLISM

The SI differed significantly among groups (F 33 =10.66; P <0.001) (clozapine <olanzapine <risperidone), with subjects treated with clozapine and olanzapine exhibiting significant insulin resistance compared with subjects treated with risperidone (clozapine vs risperidone, t 33 =−4.29; P <0.001; olanzapine vs risperidone, t 33 =−3.62; P =0.001) but not clozapine and olanzapine (t 33 =−0.67; P =0.51). While SI varies across studies and ethnic groups, we rely on data from the general population to understand the direction of insulin resistance. 34-36 The SI is inversely proportional to insulin resistance (lower SI indicates greater insulin resistance or less insulin sensitivity).

Insulin resistance calculated by the HOMA-IR also differed significantly among groups (F 33 =4.92; P =0.01) (clozapine >olanzapine >risperidone) treated with clozapine vs risperidone (t 33 =2.94; P =0.006) and olanzapine vs risperidone (t 33 =2.42; P =0.02) but not clozapine and olanzapine (t 33 =0.52; P =0.61). Both the clozapine and olanzapine groups displayed elevations in HOMA-IR compared with the risperidone group. The HOMA-IR and SI were significantly inversely correlated for patients treated with olanzapine (r =−0.72; P =0.01) and risperidone (r =−0.67; P =0.02) but not clozapine (r =−0.41; P =0.18).

Figure 1 and Figure 2 show the distribution of the primary outcome measures of the 3 groups, plotted by age (Figure 1) and BMI (Figure 2).

Although there was no significant difference among groups for AIRG (F 33 =1.59; P =0.22) or disposition index (F 33 =0.90; P =0.42), there was a significant group effect difference in SG (F 33 =4.18; P =0.02) (clozapine <olanzapine <risperidone) and significant differences between groups comparing clozapine with risperidone (t 33 =−2.59; P =0.02) and comparing olanzapine with risperidone (t 33 =−2.34; P =0.03) but not clozapine with olanzapine (t 33 =−0.42; P =0.68). The SG values could well tolerated, and all but 1 subject were able to complete all aspects of the study.

DEMOgraphics

For the entire sample (N=36), the mean±SD age was 41.7±10.6 years with a mean±SD BMI of 25.4±2.6 kg/m². Twenty-eight (78%) were white, 8 (22%) were African American, and 30 (83%) were male. The 3 treatment groups did not differ in age, sex, race, BMI, systolic or diastolic blood pressure, family history of diabetes mellitus, use of selective serotonin reuptake inhibitors, or duration of illness or medication treatment (Table 1).

BASELINE GLUCOSE METABOLISM

There was a nonsignificant difference among groups for fasting baseline plasma glucose concentrations (F 30 =2.63; P =0.09) (Table 2). Fasting serum insulin concentrations differed among groups (F 30 =3.52; P =0.047) (clozapine >olanzapine >risperidone) with significant differences between both clozapine and risperidone (t 30 =2.32; P =0.03) and olanzapine and risperidone (t 30 =2.15; P =0.04) but not clozapine and olanzapine (t 30 =0.17; P =0.87).

GLUCOSE METABOLISM
not be calculated for 3 subjects treated with clozapine because of a "floating point error." The floating point error occurs in the face of severe insulin resistance, where SI is not distinguishable from zero and SG cannot be calculated.

**LIPIDS**

There were no significant differences comparing total cholesterol (F_{25} = 3.30; P = .054), high-density lipoprotein cho-
lesterol (F_{21}=2.07; \ P=.15), low-density lipoprotein cholesterol (F_{21}=0.39; \ P=.68), and serum triglyceride levels (F_{21}=2.92; \ P=.07) among groups (Table 2).

**NUTRITIONAL ASSESSMENT AND PHYSICAL ACTIVITY**

There were no significant differences among groups for measurements of body cell mass percentage, biceps and triceps skinfold measurements, ideal body weight, ideal body weight percentage, total body fat measured by bioelectric impedance, widest hip measurements, Modifiable Activity Questionnaire total score, leisure activity level, and occupational activity level (Table 3). Additionally, the groups did not differ on measures of energy expenditure including resting energy expenditure.

However, subscapular skinfold measurements differed significantly among groups (F_{33}=3.30; \ P=.049) (clozapine>olanzapine>risperidone) (clozapine vs olanzapine, t_{33}=1.20; \ P=.24; clozapine vs risperidone, t_{33}=2.57; \ P=.02; and olanzapine vs risperidone, t_{33}=1.37; \ P=.18). Additionally, the waist-hip ratio significantly differed among groups (F_{33}=3.62; \ P=.038) (clozapine>olanzapine>risperidone), with differences between clozapine and risperidone (t_{33}=2.69; \ P=.01) but not between olanzapine and either the risperidone (t_{33}=1.47; \ P=.15) or clozapine groups (t_{33}=1.22; \ P=.23).

**FOOD INTAKE ASSESSMENT**

There were few statistically significant differences among groups on food intake calculated on the basis of a 4-day food record (Table 4). The groups did not differ in total fat, polyunsaturated fat, saturated fat, or total daily caloric intake or total kilocalories (kilojoules) per kilogram of body weight. Only percentage of protein (F_{33}=4.46; \ P=.02) and lactose (F_{33}=4.08; \ P=.03) intake differed significantly between groups.

**CORTISOL, GROWTH HORMONE, AND LEPTIN LEVELS AND CORRELATIONS OF SERUM ANTIMYCHOTIC AGENT LEVELS WITH MEASURES OF GLUCOSE METABOLISM**

There were no significant among-group differences in fasting serum cortisol and growth hormone levels. However, as leptin concentrations differ between men and women, controlling for sex, there was a significant difference among groups (F_{32}=30.86; \ P<.001) (clozapine>olanzapine>risperidone) and between clozapine and risperidone (t_{32}=2.44; \ P=.02) and olanzapine and risperidone (t_{32}=2.30; \ P=.03) but not clozapine and olanzapine (t_{32}=0.11; \ P=.91). Within treatment groups, fasting plasma glucose and serum insulin levels, SI, and SG did not correlate with dose or serum antipsychotic...
There was a significant change in insulin sensitivity, in normal sub-
glycemic-clamp technique, primarily used to assess insulin sen-
itivity measured by both SI and HOMA-IR compared with normal subjects.

Our finding of reduced glucose effectiveness in patients taking clozapine and olanzapine compared with risperidone is also consistent with findings reported in patients with type 2 diabetes mellitus. Whereas a reduced SG is characteristic of type 2 diabetes mellitus, and rarely has been reported in women treated with nor-
gestrel, a reduction in SG is not found in obese subjects.34,48 The lower SG values observed in patients treated with clozapine and olanzapine could result from several mechanisms, including reduced functioning of glucose transporters49 or an impairment in the suppression of he-
aptic glucose production.50

A reduction in β-cell function was not observed in any of the treatment groups; however, considerable variability in AIRD and disposition index was apparent. Five of 36 subjects (all in the olanzapine or clozapine groups) exhibited markedly reduced AIRD in addition to re-
duced SI and SG. In fact, 2 of these individuals (1 treated with clozapine and 1 treated with olanzapine) developed type 2 diabetes mellitus within 2 years after the procedure was performed. While not statistically significant, the lower mean values for disposition index in subjects treated with clozapine and olanzapine suggests

agent concentrations. Olanzapine serum levels correlated with AIRD at a trend level (r = 0.55; P = .06), but olanzapine doses did not correlate with AIRD values. In-
sulin resistance calculated by HOMA-IR analysis correlated (positively) with olanzapine serum concentrations (r = 0.66; P = .02) and, at a trend level, with clozapine doses (r = 0.53; P = .09). Nortclozapine serum concentrations did not correlate with measures of glucose metabo-
lism, whereas 9-hydroxy-risperidone concentrations correlated with SG at a trend level (r = 0.53; P = .07).

Our finding that nonobese subjects treated with cloza-
pine and olanzapine displayed significant insulin resis-
tance measured by both SI and HOMA-IR compared with subjects treated with risperidone is consistent with the findings reported by Newcomer et al8 using a modi-
fied oral glucose tolerance test. While data from normal populations are informative in the direction of SI and glucose effectiveness, comparisons across studies are dif-
cult secondary to minor differences in procedures as well as laboratory techniques. Insulin resistance, a major but not a necessary risk factor for diabetes mellitus, rep-
resents a potential pathway to type 2 diabetes mellitus over time. We would expect that patients who experi-
ence greater weight gain or BMI with these antipsychotic agents than the nonobese subjects in our study would exhibit even greater degrees of insulin resistance than we observed.54

Sowell et al17 studied insulin secretion using a hyper-
glycemic-clamp technique, primarily used to assess in-
sulin secretion and not insulin sensitivity, in normal sub-
jects following a 15- to 17-day single-blind trial of olanzapine (n = 17), risperidone (n = 13), and placebo
(n = 18). There was a significant change in insulin sen-
itivity in the olanzapine group and not the risperidone group, consistent with our findings. The authors as-
cribed this change to weight gain, based on the regression analysis. As insulin response must be considered in the context of insulin sensitivity, which was not accu-
ately measured in the study using a hyperglycemic clamp, the study did not adequately assess whether olanzapine or risperidone impaired insulin-secretion functioning. Ad-
ditionally, the study may not have been adequate to de-
tect differences because of the small sample size, brief exposure to antipsychotic drugs, and the possible difference in vulnerability in patients with schizophrenia com-
pared with normal subjects.

Table 3. Anthropometric Measurements of Test Subjects*

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Clozapine (n = 12)</th>
<th>Olanzapine (n = 12)</th>
<th>Risperidone (n = 12)</th>
<th>P Value</th>
<th>Clozapine-Risperidone</th>
<th>Clozapine-Olanzapine</th>
<th>Olanzapine-Risperidone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass index, kg/m²</td>
<td>25.7 ± 2.3</td>
<td>25.3 ± 3.3</td>
<td>25.0 ± 2.1</td>
<td>.81</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bicep skinfold, mm</td>
<td>8.6 ± 3.2</td>
<td>8.8 ± 5.0</td>
<td>6.3 ± 3.8</td>
<td>.32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triceps skinfold, mm</td>
<td>18.1 ± 4.4</td>
<td>15.0 ± 6.3</td>
<td>14.2 ± 6.3</td>
<td>.23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subscapular skinfold, mm</td>
<td>19.2 ± 5.5</td>
<td>16.4 ± 6.7</td>
<td>13.1 ± 5.1</td>
<td>.049</td>
<td>.02</td>
<td>.24</td>
<td>.18</td>
</tr>
<tr>
<td>Suprailliac skinfold, mm</td>
<td>20.4 ± 6.4</td>
<td>21.7 ± 8.9</td>
<td>15.3 ± 6.2</td>
<td>.09</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body cell mass, %</td>
<td>39.7 ± 3.1</td>
<td>41.5 ± 4.7</td>
<td>41.7 ± 5.6</td>
<td>.50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioimpedence analysis, % body fat</td>
<td>25.3 ± 3.9</td>
<td>24.7 ± 7.0</td>
<td>23.3 ± 6.8</td>
<td>.69</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist circumference (iliac crest), cm</td>
<td>97.8 ± 9.4</td>
<td>95.7 ± 9.6</td>
<td>90.4 ± 7.6</td>
<td>.12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.99 ± 0.09</td>
<td>0.95 ± 0.07</td>
<td>0.91 ± 0.06</td>
<td>.04</td>
<td>.01</td>
<td>.23</td>
<td>.15</td>
</tr>
<tr>
<td>Widest hip circumference, cm</td>
<td>99.1 ± 9.2</td>
<td>100.6 ± 6.2</td>
<td>99.6 ± 6.3</td>
<td>.86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ideal body weight, %</td>
<td>117.0 ± 12.2</td>
<td>113.9 ± 13.6</td>
<td>104.3 ± 13.0</td>
<td>.06</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAQ total score</td>
<td>16.0 ± 11.2</td>
<td>12.6 ± 15.5</td>
<td>8.5 ± 9.8</td>
<td>.34</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Occupational†</td>
<td>7.2 ± 9.0</td>
<td>5.1 ± 10.0</td>
<td>2.7 ± 4.3</td>
<td>.48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leisure†</td>
<td>8.8 ± 7.5</td>
<td>7.9 ± 12.5</td>
<td>6.4 ± 6.4</td>
<td>.82</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting energy expenditure, kcal/d</td>
<td>1804 ± 426</td>
<td>1747 ± 432</td>
<td>1613 ± 381</td>
<td>.52</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: MAQ, Modifiable Activity Questionnaire (average hours of activity per week).
SI conversion: To convert kilocalories to kilojoules, multiply by 4.2.
*Values are expressed as mean ± SD.
†Average hours of activity per week.
that these drugs may restrict the normal β-cell response to the development of insulin resistance.

Although treatment groups were matched for weight, both clozapine and olanzapine are associated with greater mean weight gain than other atypical antipsychotic agents,53 and our sample significantly differed on waist-hip ratio and subscapular skinfold measurements. Waist measures may thus be a better predictor of insulin resistance and risk for type 2 diabetes mellitus than weight gain in patients treated with atypical antipsychotic agents. Visceral adiposity has been associated with hyperinsulinemia, dyslipidemia, impaired glucose tolerance, and increased risk for cardiovascular disease.52-54 A study of 2964 elderly men and women found that approximately one third of men and less than half of women with type 2 diabetes were obese.55 Despite similar amounts of subcutaneous thigh fat, intermuscular and visceral abdominal fat were higher in subjects with type 2 diabetes and impaired glucose tolerance than in subjects with normal glucose tolerance.55 Finally, there was a significant difference in leptin levels, controlling for sex, in our study. Leptin is important for the control of body weight and may reflect differences in body fat distribution.

It is possible that schizophrenia is associated with insulin resistance and diabetes mellitus independent of pharmacological treatment.55 First-episode, drug-naïve patients with schizophrenia (n = 26) were found to have higher fasting plasma glucose, insulin, and cortisol levels compared with age-matched healthy subjects.55 Elevations of serum cortisol levels have previously been linked to the acute stress of psychosis56,57 and could contribute to impaired glycemic control. In our sample of psychiatrically stable subjects with schizophrenia, serum cortisol levels were not elevated, which may reflect the tendency of antipsychotic agents to decrease plasma cortisol levels.61

There are a number of limitations to this study. Because drug treatment was not randomized and assessment was cross-sectional, the finding of an association between olanzapine and clozapine treatment and impairment of glucose metabolism cannot be conclusively established as a causal relationship. In addition, the exclusion of obese subjects may limit the generalizability of our findings. Nevertheless, the cross-sectional assessment of psychiatrically stable, nonobese patients well-matched for type 2 diabetes mellitus risk factors does overcome other important methodological considerations as discussed earlier, and our findings, which are consistent with other reports in the literature, raise potentially important clinical concerns. Future studies that include larger samples, unmedicated patients, and varying durations of prospective antipsychotic agent exposure can address some of the limitations of this study design. Finally, because the mean SI in subjects treated with risperidone was greater than reported in the general population, the potential for type 1 error exists; therefore, replication of these findings is necessary.

### CONCLUSIONS

Psychiatrists and primary care professionals should be aware that patients treated with clozapine and olanzapine may be at increased risk for insulin resistance, even if not obese. Insulin resistance is associated with hyperlipidemia, hypertension, and cardiovascular disease and over time may increase the risk for diabetes mellitus in vulnerable individuals. Patients treated with these agents should be routinely screened, counseled to reduce risk, and provided early interventions.56,57 Established guidelines for monitoring and assessing patients’ risk for dia-

---

**Table 4. Nutrient Intake in Subjects Treated With Atypical Antipsychotic Agents**

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Clozapine (n = 12)</th>
<th>Olanzapine (n = 12)</th>
<th>Risperidone (n = 12)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total energy, kcal</td>
<td>2199 ± 1094</td>
<td>2583.6 ± 1386</td>
<td>1921 ± 585</td>
<td>.33</td>
</tr>
<tr>
<td>Total kcal/kg body weight</td>
<td>28.1 ± 12.8</td>
<td>31.9 ± 15.0</td>
<td>26.5 ± 8.6</td>
<td>.56</td>
</tr>
<tr>
<td>Carbohydrate, % total energy</td>
<td>49.8 ± 5.1</td>
<td>51.0 ± 9.4</td>
<td>57.4 ± 9.1</td>
<td>.06</td>
</tr>
<tr>
<td>Protein, % total energy</td>
<td>16.7 ± 3.5</td>
<td>14.8 ± 3.1</td>
<td>12.9 ± 2.7</td>
<td>.02</td>
</tr>
<tr>
<td>Total fat, g</td>
<td>85.0 ± 45.6</td>
<td>98.7 ± 60.1</td>
<td>64.1 ± 20.7</td>
<td>.18</td>
</tr>
<tr>
<td>Fat, % total energy</td>
<td>34.3 ± 5.6</td>
<td>33.8 ± 8.4</td>
<td>29.7 ± 5.4</td>
<td>.18</td>
</tr>
<tr>
<td>Cholesterol, mg</td>
<td>335 ± 231</td>
<td>326.6 ± 229.1</td>
<td>272.7 ± 129.0</td>
<td>.72</td>
</tr>
<tr>
<td>Polysaturated fat-saturated fat ratio</td>
<td>0.5 ± 0.2</td>
<td>0.8 ± 0.7</td>
<td>0.6 ± 0.3</td>
<td>.26</td>
</tr>
<tr>
<td>Saturated fat, g</td>
<td>33.4 ± 20.3</td>
<td>35.0 ± 26.0</td>
<td>21.2 ± 4.7</td>
<td>.17</td>
</tr>
<tr>
<td>Starch, g</td>
<td>113.2 ± 71.0</td>
<td>124.9 ± 94.5</td>
<td>106.3 ± 39.0</td>
<td>.25</td>
</tr>
<tr>
<td>Fiber, g</td>
<td>15.3 ± 7.2</td>
<td>14.7 ± 7.3</td>
<td>13.5 ± 4.8</td>
<td>.50</td>
</tr>
<tr>
<td>Glucose, g</td>
<td>28.7 ± 18.1</td>
<td>34.6 ± 26.0</td>
<td>38.7 ± 19.5</td>
<td>.56</td>
</tr>
<tr>
<td>Fructose, g</td>
<td>27.9 ± 19.3</td>
<td>33.4 ± 29.0</td>
<td>34.2 ± 18.1</td>
<td>.78</td>
</tr>
<tr>
<td>Galactose, g</td>
<td>0.2 ± 0.2</td>
<td>0.1 ± 0.1</td>
<td>0.1 ± 0.1</td>
<td>.33</td>
</tr>
<tr>
<td>Lactose, g</td>
<td>22.7 ± 17.5</td>
<td>14.0 ± 8.2</td>
<td>8.5 ± 7.0</td>
<td>.03</td>
</tr>
<tr>
<td>Maltose, g</td>
<td>1.6 ± 1.5</td>
<td>2.2 ± 1.8</td>
<td>2.9 ± 2.7</td>
<td>.42</td>
</tr>
<tr>
<td>Sucrose, g</td>
<td>40.1 ± 25.0</td>
<td>66.4 ± 40.2</td>
<td>58.4 ± 38.4</td>
<td>.25</td>
</tr>
<tr>
<td>Alcohol, g</td>
<td>0.1 ± 0.2</td>
<td>3.1 ± 7.1</td>
<td>3.4 ± 5.7</td>
<td>.25</td>
</tr>
</tbody>
</table>

SI conversion: To convert kilocalories to kilojoules, multiply by 4.2.

*Values are expressed as mean ± SD.
betes and cardiovascular disease exist. Waist and hip measurements, along with monitoring lipid levels, may be a useful tool for patient follow-up and assessing the change in risk for insulin resistance and type 2 diabetes mellitus, consistent with recent guidelines.

Submitted for Publication: November 3, 2003; final revision received April 16, 2004; accepted July 9, 2004.

Author Affiliations: Schizophrenia Program (Drs Henderson, Evins, and Goff and Ms Borba and Daley), Diabetes Research Center (Dr Cagliero), MGH Weight Center and Endocrine Unit (Dr Copeland), Mallinckrodt General Clinical Research Center (Drs Cagliero and Schoenfeld and Mr Hayden and Ms Anderson); Biostatistics Center (Dr Schoenfeld and Mr Hayden), Biochemistry Research (Ms Anderson), Massachusetts General Hospital, Boston; University of Texas at Arlington School of Nursing, Arlington (Dr Weber); Departments of Biostatistics and Nutrition Sciences, University of Alabama at Birmingham, Birmingham (Dr Allison); Harvard Medical School, Boston (Drs Henderson, Cagliero, Copeland, Evins, Schoenfeld, and Goff).

Correspondence: David C. Henderson, MD, Freedom Trail Clinic, 25 Stanford St, Boston, MA 02114 (dhenderson@partners.org).

Funding/Support: This study was supported by grant 5MO1RR01066-24 from the National Institutes of Health General Clinical Research Center, Bethesda, Md; a Young Investigator Award from the National Alliance for Research of Schizophrenia and Depression, Great Neck, NY (Dr Henderson); and an Investigator-Initiated Independent Research Grant from Janssen Pharmaceutica, Beerse, Belgium.

Acknowledgment: We thank David Nathan, MD, director of the Massachusetts General Hospital Mallinckrodt General Clinical Research Center, Boston, for support and scientific guidance in the development and conduct of this research project.

REFERENCES


